Protein expression patterns of cell cycle regulators in operable breast cancer.
To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various breast cancer subtypes.Cyclin E1, cyclin D1, p53, p21 and p27 were evaluated with immunohistochemistry in 1077 formalin-fixed paraffin-embedded tissues from b...
Main Authors: | Flora Zagouri, Vassiliki Kotoula, George Kouvatseas, Maria Sotiropoulou, Triantafyllia Koletsa, Theofani Gavressea, Christos Valavanis, Helen Trihia, Mattheos Bobos, Georgios Lazaridis, Angelos Koutras, George Pentheroudakis, Pantelis Skarlos, Dimitrios Bafaloukos, Niki Arnogiannaki, Sofia Chrisafi, Christos Christodoulou, Pavlos Papakostas, Gerasimos Aravantinos, Paris Kosmidis, Charisios Karanikiotis, George Zografos, Christos Papadimitriou, George Fountzilas |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5552326?pdf=render |
Similar Items
-
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.
by: George Fountzilas, et al.
Published: (2013-01-01) -
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
by: Fountzilas George, et al.
Published: (2012-10-01) -
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
by: Angelos Koutras, et al.
Published: (2018-01-01) -
Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
by: Eleni Timotheadou, et al.
Published: (2017-08-01) -
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
by: George Fountzilas, et al.
Published: (2012-01-01)